843666-40-0
C22H42O4
370.6
0.950±0.06
98% min (HPLC)
68
White to off-white powder
Semaglutide
GLP-1
N
500 kg Batch quantity
25 kg
20 tons
2019
ISO 9001;ISO 14001;ISO 45001
Availability: | |
---|---|
Supply Chain
As of August 26, 2024, there are 202 potential suppliers manufacturing Semaglutide intermediate mono-tBu stearate (CAS No. 843666-40-0), including 52 traders, 113 factories and 37 labs, among which:
- The 25th percentile has an average registered capital of 1 million CNY;
- The 50th percentile has an average registerd capital of 3 million CNY;
- The 75th percentile has an average registered capital of 10 million CNY.
Feeling overwhelmed? Contact Unibest if you need us to quality-check other sources to strengthen your supply chain or to find a tailored solution for your specific procurement request.
Usage and ROS Analysis
mono-tBu-stearate, CAS No. 843666-40-0, is an Semaglutide side chain synthesized from the C18 fatty acid (CAS No. 871-70-5).
There are two routes that would yield Semaglutide side chain CAS No. 1662688-20-1. One is through solid-phase synthesis (lower part) while the other is not (upper part). Both routes converge into this Semaglutide side chain tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu, CAS No. 1118767-16-0.
The solid phase synthesis building blocks involves three moieties including Fmoc-AEEA (CAS No. 166108-71-0), Fmoc-Glu-OtBu (CAS No. 84793-07-7), and this compound mono-tBu-stearate (CAS No. 843666-40-0).
The other route does not involve solid phase synthesis. It starts from the C18 fatty acid (CAS No. 871-70-5), giving the mono-tBu-stearate. Then mono-tBu-stearate attaches with Glu, and AEEA-dimer.